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CYTOTOXIC drugs are being used increasingly in the treatment of advanced
malignant disease, and a great variety ofthese agents is now available. However,
individual tumours, even those which appear to be identical by histological and
other criteria, may differ considerably in their response to the drugs. Therefore
a reliable method of assessing the effect of cytotoxic drugs on human tumour cells
in the laboratory, which would allow the most suitable agent to be selected for
clinical use would be of value.
The effects ofcytotoxic drugs on human tumour cells have often been examined
in vitro, but these investigations have failed to produce consistently reliable
results. It was therefore felt that an examination of the response of tumour cells
to cytotoxic drugs under less abnormal conditions in vivo would be of interest,
and might yield results with a more valid clinical application.
In order to achieve this, grafts of human tumours must be induced to obtain
a blood supply and to grow following transplantation to a laboratory animal host.
The cheek pouch ofthe golden hamster is known to possess immunological privilege
in the sense that grafts of homologous and heterologous tissue will often survive
for long periods at this site. Billingham, Ferrigan and Silvers (1960) and Cohen
(1961) have demonstrated that, although skin homografts and heterografts to the
trunk ofthe hamster are normally rejected within 12 days, grafts to the lateral wall
of the cheek pouch will often survive for many months. And it has also been
shown that a significant proportion of human tumours will survive and grow for
short periods at the cheek pouch, especially if the host is conditioned with small
doses of cortisone. Handler, Davis and Sommers (1956) reported that 38% of 68
human tumours showed histological evidence of survival and growth 5-58 days
after transplantation, and Patterson, Patterson and Chute (1957) observed growth
in 52% of 90 human tumours. A small proportion (10%) grew well, and it was
possible to transfer these to further hamster hosts.
All the available evidence suggests that human tumours maintain their
functional and histological identity after transplantation to the hamster cheek
pouch. Toolan (1955) has stressed that very little alteration in histological
structure takes place. Levan (1956) has demonstrated that human tumours
retain their chromosomal identity. Korngold and Lipari (1955) and Yohn et al.
(1962) have reported that serially propagated human tumours retain their tumour
antigens. Pierce, Dixon and Verney (1958) and Hertz (1959) have shown that
hormonal function can be maintained by human testicular tumours and chorio-
carcinomas growing at the hamster cheek pouch.
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Handler (1958) investigated the response of serially propagated tumours of
human origin to a variety ofcytotoxic agents, and demonstrated that the response
of a tumour growing on the cheek pouch can be related to the dose of drug ad-
ministered intraperitoneally. Reproducible dose-response curves were obtained.
Burt et al. (1966) and Sommers, Friedell and Robinson (1966), using different
tumours and cytotoxic agents, have confirmed these findings.
Sanders (1963) has introduced an observation chamberwhich enables the lateral
wall of the hamster cheek pouch and any tissue transplanted to it to be examined
microscopically in vivo. The chamber consists of 2 simple perspex components
which fit together to enclose part of the wall of the cheek pouch and any tissue
grafted to it (Fig. 1 and 2). Introduction of a light source to the lumen ofthe
pouch provides transillumination for direct microscopy in the anaesthetised
animal. The useful life of the preparation is 2-3 weeks and during this time any
changes which take place in the cheek pouch membrane, or in the tissue trans-
planted to it, can be readily observed and photographed.
Goodall, Sanders and Shubik (1965) and Warren and Shubik (1966) have
studied the vascularisation and growth of hamster tumours transplanted to the
chamber. Delorme et al. (1965) have used the chamber to examine the growth of
human tumour cell suspensions, and Ellis and Sewell (1966) have reported vascu-
larisation and growth of fragments of human lung, bladder and stomach tumours
within the chamber. It was therefore thought that the technique would be
suitable for an examination in vivo ofthe response ofhuman tumours to cytotoxic
drugs.
METHODS
Transplantation
Golden hamsters of either sex, 25-40 weeks old and weighing 100-200 g. were
used. In each case the observation chamber was inserted in the right cheek
pouch only. A modified pattern, described by Sewell (1966), of Sanders' (1963)
original observation chamber was used. Thetechniquesofinsertionofthechamber
and of microscopical examination have been described in detail by Goodall,
Sanders and Shubik (1965) and Sewell (1966).
Tumour specimens were obtained as soon as possible after removal from the
patient. If a large tumour mass was removed a small portion ofit, usually about
0 5-1'0 cu.cm. in size, was then selected and excised with sterile instruments. In
some instances only a small biopsy specimen was obtained. Care was always
taken to choose healthy viable neoplastic tissue. Areas of obvious necrosis or
infection were avoided.
The tumour specimen was immediately placed in sterile tissue culture medium
at 40 C. (T.C. 199 Glaxo, containing penicillin 200 ,u/ml. and streptomycin 100 jug./
ml.). Tumour fragments measuring as nearly as possible 1 cu.mm. were then cut
from the specimen using a sterile No. 22 Bard Parker scalpel blade. Care was
taken to choose pieces of approximately equal size for transplantation. In most
cases the time between excision of tissue from the patient and transfer to the
hamster pouch was less than 1 hour. In all cases it was less than 2 hours.
Grafts from 32 human tumours were transplanted to cheek pouch chambers in
124 hamsters (Table I). Tumours from 10 different sites of origin were used.
Carcinomas of the breast and gastrointestinal tract predominated in the series
which also included neoplasms of the bronchus, bladder, skin, connective tissue
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and liver. Tissue from each tumour was transplanted to 2-10 hamsters at a time.
In the majority of cases 4 hamsters were used. The tumours were examined
microscopically in vivo every 1-2 days for 10-21 days. At the end of this period
the animals were killed. The implants were then excised and fixed in formalin for
histological examination.
TABLE I.-TheSites ofOrigin, Types and Numbers ofHuman Tumours Transplabnted
to Golden Hamsters
Number Number
of of
Tumour origin Tumour type tumours implants
Breast . Adenocarcinoma 6 18
Colon . Adenocareinoma 6 21
Rectum . . Adenocarcinoma . 5 19
Stomach . . Adenocarcinoma . 4 17
Pancreas . Adenocareinoma . 2 7
Bronchus . Squamous cell carcinoma 1 4
Spheroidal cell carcinoma 1 4
Bladder . . Transitional cell careinoma 1 . 4
Skin . Malignant melanoma 1 10
Squamous cell carcinoma 1 4
Hidradenoma . 1 . 4
Connective tissue . Fibrosarcoma . 1 4
Mesenchymal sarcoma . 1 . 4
Liver . . . Hepatoma 1 . 4
Number of primary sites = 10
Number of tumours = 32
Number of implants = 124
Increase in size of individual tumour grafts was assessed by measurement
in vivo, and confirmed by subsequent histological examination. It was not
possible to estimate the volume of the implants because sufficiently accurate
measurements of tumour depth could not be obtained. Therefore, as the depth
ofeach implant remained almost constant within the rigid confines ofthe chamber,
and was always less than 0 5 mm., an estimate oftumour surface area (T.S.A.) was
used as the index oftumour size (Fig. 3). This was defined as the area oftumour
visible on in vivo microscopy, and was measured with a micrometer eyepiece. If
the T.S.A. increased by 100% or more, growth was said to have occurred. This
was always confirmed by subsequent histological examination of the implant.
EXPLANATION OF PLATES
FIG. 1.-The Sanders' observation chamber in place. A graft of human tumour is visible in the
centre of the chamber.
FIG. 2.-The components of the observation chamber. x 1-5.
FIG. 4.-Cheek pouch graft of human sweat gland tumour 11 days after transplantation. ep
Cheek pouch tissue. H and E x 75.
FIG. 5.-Cheek pouch graft of human rectal carcinoma 11 days after transplantation to a hamster
treated with 0 5 mg./kg./day x 7 of nitrogen mustard. Tumour cells are visible, T. cp =
Cheek pouch tissue. H and E x 115.
FIG. 6.-Cheek pouch graft ofhuman colonic carcinoma 11 days after transplantation to a hamster
treated with 0 5 mg./kg./day x 7 of nitrogen mustard. No tumour cells are visible within the
graft, g. ep = Cheek pouch tissue. H and E x 60.BRITISH JOURNAL OF CANCER.
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Cytotoxic agents
Nitrogen mustard and methotrexate were the drugs used. Sixteen human
tumours were used for cytotoxic studies (Table II). The response of implants
from 10 tumours to both drugs was examined, and the response of implants from
6 tumours to either drug alone. One or more untreated control implants were
used for comparison in every case.
Cytotoxic treatment was started as soon as the tumour implants were observed
to have been completely vascularised. The cytotoxic agents were administered
intraperitoneally by single, daily injections for 7 successive days. The dosages
were calculated, using the criteria of Freireich et al. (1966), to be approximately
equivalent to total human dose levels of 0 4 mg./kg. of nitrogen mustard and
2*0 mg./kg. of methotrexate. In each case the total dose administered to the
0X0
T.S.A=.RTD ,~~~~~=
FiG. 3.-The estimation of tumour surface area (T.S.A) in vivo within the observation
chamber. DI and D2, tumour diameters.
hamster was 3-5 mg./kg. (0.5 mg./kg. X 7) of nitrogen mustard and 17*5 mg./kg.
(2.5 mg./kg. X 7) of methotrexate.
Implants which grew during the period of cytotoxic therapy and remained
viable were classified as " drug-resistant ". Viability was assessed on histological
examination of the grafts. Those which failed to grow and were subsequently
lound to be non-viable were classified as " drug-sensitive ". Intermediate results
were classified as" equivocal ". These findings were only accepted if untreated
control implants showed measurable growth, and remained histologically viable
during the period of the study.
RESULTS
Vas8cularisation and growth
It was observed that either the tumour implants received a blood supply by
ingrowth of host blood vessels within a week of grafting, or they remained
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TABLE II.-The Response to Cytotoxic Drugs of Human Tumours Transplanted to
Golden Hamsters
Tumour type
Carcinoma of breast
Carcinoma of colon .
Carcinoma of colon .
Carcinoma of colon .
Treatment
Control
Control 210
Nitrogen mustard . 132
Methotrexate . 26
Control . 225
Control . 775
Nitrogen mustard . 0
Control 468
Control . 356
Nitrogen mustard . 0
Methotrexate . 22
* Control
Control
Control
Methotrexate
Increase
in T.S.A. Growth
(%) (3100%) Viability
403 + * + 4
+
+
+
+
1-
+
+
+
0
0
50
0
Carcinoma of rectum
Carcinoma of rectum
Carcinoma of rectum
Carcinoma of rectum
Carcinoma of stomach
Carcinoma of stomach
Carcinoma of stomach
Control . 508
Nitrogen mustard . 132
Methotrexate . 132
Control . 210
Control . 356
Nitrogen mustard . 0
Methotrexate . 0
Control . 118
Control . 260
Nitrogen mustard . 0
Methotrexate . 0
Control . 488
Nitrogen mustard . 0
Control . 221
Control . 390
Nitrogen mustard . 176
Control . 584
Control . 584
Nitrogen mustard . 90
Methotrexate . 132
* Control
Control
Control
Methotrexate
Carcinoma of bronchus . Control
Methotrexate
228
356
188
0
+
+
±
+
+
+
+
+
+
± * ±
±
+
+
127 . +
O 0
. Equivocal
. Resistant
. Equivocal
Sensitive
* Sensitive
Sensitive
. Sensitive
* +
(not
obtained)
+ . Resistant
* +
- . Sensitive
- . Equivocal
* +
* +
- . Sensitive
* ±
- .Sensitive
Malignant melanoma * Control . 390
Control . 213
Nitrogen mustard . 500
Methotrexate . 290
Response to
drug
. Equivocal
* Sensitive
Sensitive
. Sensitive
* Sensitive
+
+
+
±
+
+ Resistant
. ResistantCYTOTOXIC AGENTS AND HUMAN TUMOURS
TABLE II.-Continued.
Increase
in T.S.A. Growth Response to
Tumour type Treatment (%) ( 100%) Viability drug
Hidradenoma . . Control . 136 . + +
Nitrogen mustard 0 . - . + . Equivocal
Methotrexate 0 . - . + . Equivocal
Mesenchymal sarcoma . Control . 72 . - . +
Control . 72 . - +
Nitrogen mustard . 0 -
Methotrexate . 0 - . -
Hepatoma . Control . 306 + . +
Nitrogen mustard 224 . + . - . Equivocal
Methotrexate . 0 - . Sensitive
persistently avascularduringtheobservation periodof1 0-21 days. Thedistinction
between the 2 groups was clear-cut, and no implant which was avascular at the end
of 1 week was ever observed to obtain a blood supply subsequently.
Of the 32 tumours examined 20 were vascularised and 12 remained avascular.
The time taken for implants from different tumours to obtain a blood supply
varied from 3-7 days, but the response to implants ofthe same tumour in different
hamsters was consistently similar. Grafts ofthe tumours which were vascularised
all received a blood supply within 1-2 days ofeach other; grafts oftumours which
did not receive a blood supply all remained avascular. Implants from 14 tumours
were observed to grow within the chamber. These implants always received a
blood supply before they began to increase in size. Six tumours which obtained
a blood supply failed to grow. Implants of 12 tumours which were not vascular-
ised also did not grow. Histological examination revealed that implants which
had been vacularised usually, but not invariably, contained viable tumour cells,
whereas implants which had failed to receive a blood supply within a week of
transplantation were always non-viable.
These observations showed that implants from individual human tumours are
able to induce a consistently similar microvascular response in different hamsters.
This in turn suggested that the behaviour of human tumours within the Sanders'
observation chamber is probably sufficiently reproducible for valid results to be
obtained from studies with cytotoxic drugs.
Response to cytotoxic drugs
Grafts from 14 ofthe 16 tumours studied increased in size after transplantation
to the cheek pouches of untreated control animals (Table II). In most of these
cases growth was relatively slight, and in no instance was the chamber cavity
completely filled by tumour tissue. Histological examination after the observa-
tion period of 10-14 days showed that these implants contained viable tumour
cells (Fig. 4) and that mitotic figures were present. Comparison with sections of
the parent neoplasm demonstrated that tissue differentiation was usually retained
by the tumour implants.
Two tumours failed to grow in control animals. Examinations of implants
from one, a mesenchymal sarcoma, revealed viable tumour cells, but implants of
the other, a colonic carcinoma, contained only a few cells ofpossible tumour origin.
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The effect of nitrogen mustard was studied on implants of 13 tumours (Table
III). Five showed measurable growth during the period of cytotoxic therapy.
On histological examination 2 ofthese were assessed as viable and 3 as non-viable.
TABLE III.-The Response to Nitrogen Mustard of Cheek-pouch Grafts
ofHuman Tumours
Tumours
13
Growth No growth
5S 8
Viable Non-viable Viable Non-viable
2 3 2 6
Resistant Equivocal Sensitive
Eight implants did not grow. Two contained viable tumour cells (Fig. 5), but the
remaining 6 were not viable (Fig. 6).
The effect of methotrexate was also studied on implants from 13 tumours
(Table IV). Three showed measurable growth during the period of cytotoxic
therapy. On histological examination 2 of these were assessed as viable and one
TABLE IV.-The Response to Methotrexate of Cheek-pouch Grafts of
Human Tumours
Tumours
13
Growth No growth
3 14)
Viable Non-viable Viable Non-viable
2 1 1 9
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as non-viable. Ten implants did not grow. One contained viable tumour cells
but the remaining 9 were not viable.
On the basis of these observations 6 tumours were assessed as sensitive to the
action of nitrogen mustard. These were tumours which did not grow and were
found to be non-viable after therapy. In one case, however, this finding was
invalidated because 2 control implants also failed to grow. Two tumours which
grew during treatment and remained viable were judged to be resistant. The
results with the remaining 5 tumours were equivocal.
Nine tumours were assessed as sensitive to the action of methotrexate. In 2
of these cases this finding was invalidated because control implants also failed to
grow. Two tumours which grew during treatment and remained viable were
judged to be resistant. The results with the remaining 2 tumours were equivocal.
DISCUSSION
The idea ofusing an in vivotechnique to predict the clinical efficacy ofcytotoxic
agents is attractive in theory. But before a technique sufficiently reliable to be of
practical value can be established, the problems of obtaining growth of heterolo-
gous tumours, and then ofassessing the effects ofcytotoxic drugs on these growing
tumours have to be overcome.
The present studies confirm that many human tumours will grow for short
periods at the hamster cheek pouch. They also demonstrate that the Sanders'
observation chamber can be conveniently used to measure thegrowth and response
to cytotoxic drugs of these tumours in vivo. The finding that the microvascular
response induced by grafts of individual human tumours, and the growth and
viability of these implants, is very similar in different hamsters suggests that it
should be possible to obtain consistent and reproducible results from studies with
cytotoxic drugs.
If the results of cytotoxic studies on human tumour grafts growing in the
hamster are to have a practical, clinical application, the situation in the animal
host must approximate as closely as possible to that which obtains clinically. In
particular the agents being tested should be carried to and from the grafted cells
naturally in the blood-stream, as usually occurs in the patient, and should reach
these cells in concentrations similar to those attained in the clinical state.
Microscopical studies in vivo have demonstrated that cheek pouch implants of
cellular human tumours regularly obtain a blood supply within a week of trans-
plantation. Host capillaries grow in and rapidly form an extensive vascular
network within the graft. Goodall, Sanders and Shubik (1965), using hamster
tumours, have reported that these vessels form a pattern characteristic for each
tumour type. Kligerman and Henel (1961) have noted that new tumour vessels
in a transplanted murine tumour responded normally to stimulation with drugs
such as adrenalin and acetylcholine. These findings suggest that the blood vessels
within a tumour graft, although of alien origin, are anatomically and functionally
normal, and essentially similar to the tumour vessels in the natural host. This
adds support to the view that, provided the drug is blood-borne in both situations,
there is no reason why the effect of a cytotoxic agent on a cheek pouch tumour
graft should not be the same as the clinical effect ofthe drug upon the same tumour.
The problem ofensuring that cytotoxic agents reach implanted tumour cells in
concentrations identical with those obtained clinically has not been completely
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solved. Pinkel (1958) and Freireich et al. (1966) have claimed that the most
accurate method of obtaining comparable anti-tumour effects from cytotoxic
drugs in different species is to use dosages based upon an estimate ofbody surface
area. However, at best this is likely to produce drug activity which is only
approximately equivalent. A more precise method of correlating dosages of
cytotoxic agents in man and in the hamster will have to await a detailed examina-
tion and comparison of the response of human tumours to drugs in the 2 species.
All human neoplasms inevitably regress within a few weeks oftransplantation
to the hamster cheek pouch. Therefore, the time during which the effects of
cytotoxic drugs can be studied is limited. Any changes in the size of the grafts
during this relatively short period are likely to be small. For this reason an
accurate method of measuring the growth of tumour implants at a microscopic
level is essential if useful results are to be obtained.
The Sanders' observation chamber fulfils this need. Comparative measure-
ments in vivo and in stained microscopical sections have shown that the edge of a
grafted tumour can be delineated with sufficient accuracy within the chamber to
allow changes in graft size to be assessed. But although the growth of tumour
grafts can be measured by this means, it is not possible to recognise whether the
cells within an implant are dead or alive by observation in vivo. This can only be
determined by histological examination of the tumour after its excision from the
hamster. Therefore, a combination ofmeasurement oftumour growth in vivo and
subsequent examination of the fixed and stained implant is necessary for a full
evaluation of the effects of cytotoxic drugs on tumour grafts.
In the present studies comparison of the results obtained in animals treated
with cytotoxic drugs and in untreated controls has enabled human tumours to be
graded with regard to their sensitivity to nitrogen mustard and methotrexate.
Some of the tumours were found to be sensitive or resistant to the drugs, but in a
substantial proportion of cases the results were equivocal. In these instances the
tumours either grew during the period of cytotoxic therapy and were then found
to be non-viable at the end of treatment, or else they failed to grow but remained
viable. The significance of these findings is not certain, but possibly in the first
instance the explanation is that although the tumour implants showed some
growth during cytotoxic therapy, the cumulative effects of the drug resulted in
destruction oftumour cells by the end oftreatment. This suggests that, although
some early growth was possible, these tumours were essentially responsive to the
drugs. In the second instance the explanation would appear to be that the
cytotoxic agents, although effective in preventing cell-division, and hence tumour
growth, did not cause cytolysis. This too suggests that the tumours were respon-
sive to some extent.
The results of these experiments indicate that human tumours transplanted
to the hamster cheek pouch show demonstrably different responses to cytotoxic
drugs administered in identical doses and for identical periods of time. This
suggests that tumours growing at the cheek pouch are able to retain their indi-
vidual sensitivities to cytotoxic agents, and that in consequence it may be possible
eventually to use the cheek pouch technique to predict the very variable clinical
sensitivities of human tumours to cytotoxic drugs. However, although one
might be tempted to infer that the response of a human tumour to a cytotoxic
agent clinically is likely to be similar to its response to the same drug in the
hamster, in the final analysis this can only be established by a careful examination
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and direct comparison of the eslults obtained with individual tumours in the
hamster and in man.
SUMMIARY
The Sanders' observation chamber has been used to examine the blood supply,
growthandresponsetocytoxicdrugsofhumantumourstransplantedto the hamster
cheek pouch. Grafts from different tumours varied widely in their vascularisation
and growth but grafts from the same tumour showed a consistently similar micro-
vascular and growth pattern in different hamsters. Observations on the effect of
nitrogen mustard and methotrexate on tumour grafts suggest that human tumours
retain their individual sensitivities to cytotoxic agents while growing at the cheek
pouch, and that it may therefore be possible to use the technique to predict the
clinical response of human tumours to cytotoxic drugs.
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